In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Results Preview: Scrip's Pharma Watchlist

This article was originally published in Scrip

Executive Summary

Johnson & Johnson will kick off the big pharma financial results season on Jan. 26. The backdrop for the company's conference call on its earnings will be the restructuring of its medical devices business. On Jan. 19 it announced it would cut around 3,000 jobs to make savings of $800m-1bn. That will involve one-off charges of $2-2.4bn with about $600m to be lodged in the books of the fourth quarter just gone. J&J has promised additional details of the impact of its changes during its earnings call.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts